ZBTB16 and acute myeloid leukemia: In conclusion, this is the first report describing that ZBTB16‐RARA+AML are characterized by high incidence of ARID1A mutations, and suggesting the involvement of the SWI/SNF chromatin remodeling complexes in the clinical presentation of this AML subtype.